Literature DB >> 23355537

How I assess comorbidities before hematopoietic cell transplantation.

Mohamed L Sorror1.   

Abstract

The hematopoietic cell transplantation-comorbidity index (HCT-CI) is a comorbidity tool suited for recipients of HCT. The index has been shown to sensitively capture the prevalence and magnitude of severity of various organ impairments before HCT and to provide valuable prognostic information after HCT. Many investigators have validated the discriminative power of the HCT-CI, but others have not. One concern is the consistency in comorbidity coding across different evaluators, particularly in view of the relatively recent addition of the HCT-CI to the transplant evaluation process. In this article, comorbidity scoring was tested across different evaluators, and only a fair interobserver agreement rate could be detected. To address these issues, a brief training program is proposed here, consisting of systematic methodology for data acquisition and consistent guidelines for comorbidity coding that were summarized in a Web-based calculator. In a validation patient cohort, this training program was shown to improve the interevaluator agreement on HCT-CI scores to an excellent rate with weighted κ values in the range of 0.89 to 0.97. This proposed training program will facilitate reliable assessment of comorbidities in the clinic and for research studies leading to standardization of the use of comorbidities in prediction of HCT outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23355537      PMCID: PMC3624933          DOI: 10.1182/blood-2012-09-455063

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Authors:  Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb
Journal:  Blood       Date:  2007-09-14       Impact factor: 22.113

2.  [Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].

Authors:  Katsumichi Fujimaki; Rika Sakai; Shin Fujisawa; Hiroyuki Fujita; Masatsugu Tanaka; Maki Hagihara; Hideyuki Koharazawa; Takuya Miyazaki; Naoto Tomita; Heiwa Kanamori; Atsuo Maruta; Yoshiaki Ishigatsubo
Journal:  Gan To Kagaku Ryoho       Date:  2008-01

3.  Comorbidity and functional status are independent in older cancer patients.

Authors:  M Extermann; J Overcash; G H Lyman; J Parr; L Balducci
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

4.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.

Authors:  Nicole Birninger; Martin Bornhäuser; Markus Schaich; Gerhard Ehninger; Johannes Schetelig
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-25       Impact factor: 5.742

7.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.

Authors:  W R Sperr; F Wimazal; M Kundi; C Baumgartner; T Nösslinger; A Makrai; R Stauder; O Krieger; M Pfeilstöcker; P Valent
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

8.  Association of comorbidity with disability in older women: the Women's Health and Aging Study.

Authors:  L P Fried; K Bandeen-Roche; J D Kasper; J M Guralnik
Journal:  J Clin Epidemiol       Date:  1999-01       Impact factor: 6.437

9.  Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Authors:  Navneet S Majhail; Claudio G Brunstein; Marcie Tomblyn; Avis J Thomas; Jeffrey S Miller; Mukta Arora; Dan S Kaufman; Linda J Burns; Arne Slungaard; Philip B McGlave; John E Wagner; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2008-03       Impact factor: 5.742

10.  THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE.

Authors:  A R Feinstein
Journal:  J Chronic Dis       Date:  1970-12
View more
  65 in total

1.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Rainer F Storb; Brenda M Sandmaier; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Smita Bhatia; Fabiana Ostronoff; H Joachim Deeg; Karen L Syrjala; Elihu Estey; David G Maloney; Frederick R Appelbaum; Paul J Martin; Barry E Storer
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Authors:  Mahmoud Elsawy; Barry E Storer; Filippo Milano; Brenda M Sandmaier; Colleen Delaney; Rachel B Salit; Ahmed H Rashad; Ann E Woolfrey; Frederick R Appelbaum; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot study.

Authors:  Richard J Lin; Parastoo B Dahi; Armin Shahrokni; Saman Sarraf; Beatriz Korc-Grodzicki; Sean M Devlin; Molly A Maloy; Gunjan L Shah; Ann A Jakubowski; Sergio A Giralt
Journal:  Leuk Lymphoma       Date:  2019-06-21

4.  Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

Authors:  Brandon K C Au; Ted A Gooley; Philippe Armand; Min Fang; David K Madtes; Mohamed L Sorror; Michael J Boeckh; Christopher J Gibson; Hans Joachim Deeg; Rainer Storb; Frederick R Appelbaum; Jason W Chien; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-31       Impact factor: 5.742

5.  CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Authors:  Pere Barba; Rodrigo Martino; Qin Zhou; Christina Cho; Hugo Castro-Malaspina; Sean Devlin; Albert Esquirol; Sergio Giralt; Ann A Jakubowski; Dolores Caballero; Molly Maloy; Esperanza B Papadopoulos; José Luís Piñana; María Laura Fox; Francisco J Márquez-Malaver; David Valcárcel; Carlos Solano; Lucía López-Corral; Jorge Sierra; Miguel-Angel Perales
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-02       Impact factor: 5.742

Review 6.  Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.

Authors:  M Elsawy; M L Sorror
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

7.  Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit.

Authors:  Ulas D Bayraktar; Elizabeth J Shpall; Ping Liu; Stefan O Ciurea; Gabriela Rondon; Marcos de Lima; Marylou Cardenas-Turanzas; Kristen J Price; Richard E Champlin; Joseph L Nates
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

8.  Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation.

Authors:  P Barba; R Martino; G Orti; A Esquirol; S Perez-Hoyos; J Sierra; D Valcárcel
Journal:  Bone Marrow Transplant       Date:  2015-06-22       Impact factor: 5.483

9.  Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.

Authors:  Mahmoud ElSawy; Barry E Storer; Michael A Pulsipher; Richard T Maziarz; Smita Bhatia; Michael B Maris; Karen L Syrjala; Paul J Martin; David G Maloney; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror
Journal:  Br J Haematol       Date:  2015-05-05       Impact factor: 6.998

10.  Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Authors:  Richard J Lin; Patrick D Hilden; Theresa A Elko; Parastoo B Dahi; Armin Shahrokni; Ann A Jakubowski; Miguel-Angel Perales; Craig S Sauter; Hugo R Castro-Malaspina; Juliet N Barker; Brian C Shaffer; Roni Tamari; Esperanza B Papadopoulos; Molly A Maloy; Beatriz Korc-Grodzicki; Sergio A Giralt
Journal:  Blood Adv       Date:  2019-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.